Making the cut

What are likely to be the top 10 drug launches of 2017? 

2016 was an “unusually slow year” for drug approvals, according to US industry website Fierce Pharma

However, analysts are still predicting a range of new ‘blockbuster’ drug launches. Heading the list, according to EP Vantage’s 2017 preview, which ranks the year’s rollouts by 2022 sales, is Ocrevus (ocrelizumab), a multiple sclerosis drug from Roche.

The top 10 is:

  1. Ocrevus (ocrelizumab), Company: Roche; Disease: Multiple sclerosis; 2022 sales estimate: US$4.1 billion
  2. Dupixent (dupilumab), Companies: Sanofi and Regeneron; Disease: Atopic dermatitis;
    2022 sales estimate: $4.1 billion
  3. Semaglutide  Company: Novo Nordisk; Disease: diabetes; 2022 sales estimate: $2.2 billion
  4. Durvalumab  Company: AstraZeneca, Disease area: cancer immunotherapy, 2022 sales estimate: $1.9 billion
  5. Niraparib   Company: Tesaro; Disease: cancer; 2022 sales estimate: $1.9 billion
  6. Baricitinib  Company: Eli Lilly and Incyte; Disease: Rheumatoid arthritis; 2022 sales estimate: $1.8 billion
  7. LEE011 (ribociclib)  Company: Novartis; Disease: breast cancer; 2022 sales estimate: $1.6 billion
  8. KTE-C19 (axicabtagene ciloleucel)  Company: Kite Pharma; Disease: non-Hodgkin’s lymphoma; 2022 sales estimate: $1.4 billion
  9. Ingrezza (valbenazine)  Company: Neurocrine; Disease: tardive dyskinesia; 2022 sales estimate: $1.3 billion
  10. Spinraza (nusinersen)  Company: Biogen and Ionis; Disease: spinal muscular atrophy; 2022 sales estimate: $1.3 billion

Previous How multi-millionaire pharmacists manage their time
Next Is Australia ready for an infectious disease emergency?

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply